Stem Cell Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Stem Cell Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes Research
Transition Therapeutics announces clinical development plan for combination diabetes compound
August 14th, 2006
Transition Therapeutics Inc. (TTH), announced that it has regained exclusive ownership of the GLP1-I.N.T. technology and is moving forward with a clinical development plan to rapidly advance GLP1-I.N.T. (combination therapy of Transition's regenerative agent G1 and a GLP-1 analogue) into diabetes patients. As a growing body of evidence has been reported by clinicians and researchers worldwide, regenerative therapy has emerged as a major focus for diabetes treatment. Transition's I.N.T. products are considered regenerative candidates in clinical development. The GLP1-I.N.T. proprietary combination utilizes the regenerative and blood glucose control...
Source: Stem Cell Week (2006-08-14)
|
